Amoy Diagnostics Co., Ltd. (SHE:300685)

China · Delayed Price · Currency is CNY

17.35

+0.02 (0.12%)

Sep 1, 2026, 3:04 PM CST

-26.36% (1Y)

Market Cap	6.68B -26.7%
Revenue (ttm)	1.18B +2.8%
Net Income	338.34M +12.8%
EPS	0.84 +10.8%
Shares Out	385.74M
PE Ratio	20.60
Forward PE	17.68
Dividend	0.45 (2.39%)
Ex-Dividend Date	May 18, 2026

Volume	5,719,773
Open	18.07
Previous Close	17.33
Day's Range	17.25 - 18.07
52-Week Range	15.62 - 26.15
Beta	0.30
Analysts	Strong Buy
Price Target	28.33 (+63.29%)
Earnings Date	Aug 25, 2026

About Amoy Diagnostics

Amoy Diagnostics Co., Ltd. engages in research and development, production, sale, and supporting services of tumor precision medical diagnostic products in China and internationally. The company offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions, evaluates PARP inhibitor-related biomarkers and advances targeted treatment research in ovarian cancer; AmoyDx comprehensive panel, a sequencing-based test capable of detecting a range of alterations; AmoyDx HRD complete panel, detects genetic aberrations across HRR genes and... [Read more]

Industry Diagnostics & Research

Sector Healthcare

Founded 2008

Employees 1,175

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 300685

Full Company Profile

Financial Performance

In 2025, Amoy Diagnostics's revenue was 1.20 billion, an increase of 8.01% compared to the previous year's 1.11 billion. Earnings were 361.26 million, an increase of 41.74%.

Financial Statements

Analyst Summary

According to 5 analysts, the average rating for 300685 stock is "Strong Buy." The 12-month stock price target is ¥28.33, which is an increase of 63.29% from the latest price.

Price Target

¥28.33

(63.29% upside)

Analyst Consensus: Strong Buy

Stock Forecasts